Original Article

Non-steroidal anti-inflammatory drug use and functional outcome from ischemic cerebral events among women

Pamela M. Rist [a,d,e,*], M. Maria Glymour [e,f], E. John Orav [b,c], Eunjung Kim [a], Carlos S. Kase [g], Julie E. Buring [a,d], Tobias Kurth [a,d,h,i]

[a] Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States
[b] Division of General Internal Medicine and Primary Care, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States
[c] Department of Biostatistics, Harvard School of Public Health, Boston, MA, United States
[d] Department of Epidemiology, Harvard School of Public Health, Boston, MA, United States
[e] Department of Social and Behavioral Sciences, Harvard School of Public Health, Boston, MA, United States
[f] Department of Epidemiology and Biostatistics, University of California-San Francisco, San Francisco, CA, United States
[g] Department of Neurology, Boston University School of Medicine, Boston, MA, United States
[h] Inserm Research Center for Epidemiology and Biostatistics (U897), Bordeaux, France, Bordeaux, France
[i] College of Health Sciences, University of Bordeaux, Bordeaux, France

A B S T R A C T

Background: Use of some non-steroidal anti-inflammatory drugs (NSAIDs) has been linked to an increased risk of stroke. However, information on the impact of NSAID use on functional outcomes from stroke is limited.
Methods: Using women enrolled in the Women's Healthy Study who were free of a history of stroke or TIA at baseline, a prospective cohort study was performed to examine the impact of NSAID use on functional outcomes from stroke. Women were classified as NSAID non-user (<11 days of use in the past month), user (≥11 days of use in the past month), and missing (did not answer the question about NSAID use) during each year of the study. Possible functional outcomes were TIA or ischemic stroke with modified Rankin scale (mRS) score of 0 to 1, 2 to 3, or 4 to 6.
Results: After 15.7 mean years of follow-up, 702 TIAs, 292 ischemic strokes with mRS 0–1, 233 ischemic strokes with mRS 2–3 and 98 ischemic strokes with mRS 4–6 occurred. Compared to women who were NSAID non-users, women who were NSAID users had multivariable-adjusted (95% CI) of 1.00 (0.77, 1.29) for TIA, 1.48 (1.04, 2.10) for mRS 0–1, 0.83 (0.52, 1.33) for mRS 2–3, and 1.33 (0.68, 2.59) for mRS 4–6.
Conclusion: Results from this large cohort study suggest than NSAID use may be associated with an increased risk of ischemic stroke with mild functional outcome.

1. Introduction

Several studies have examined whether non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) are associated with an increased risk of cardiovascular events, including stroke. A meta-analysis of 26 randomized controlled trials showed that naproxen, ibuprofen, diclofenac, celecoxib, etoricoxib, rofecoxib and lumiracoxib were associated with an increased risk of stroke compared with placebo although this increase in risk was only statistically significant for diclofenac and lumiracoxib [1]. A prospective cohort study among healthy individuals showed that diclofenac use was associated with a significantly increased risk of stroke [2]. However, a cohort study among Medicaid enrollees found a significantly increased risk of stroke among rofecoxib and valdecoxib users, but not among diclofenac, celecoxib, ibuprofen, naproxen or indomethacin users [3]. In a

population of Australian veterans, incident use of any NSAID was associated with an increased risk of hospitalization for a stroke [4].

While several studies have examined the association between non-aspirin NSAID use and risk of stroke, little information exists on the impact non-aspirin NSAID use may have on functional outcomes from stroke in initially healthy populations. Determining if NSAID use impacts functional outcomes from stroke may help inform decisions about NSAID usage in populations without a history of stroke. For example, if the risk of stroke is low, but the risk of a poor functional outcome is high, more caution when prescribing non-aspirin NSAIDs might be warranted.

Using data from a large prospective cohort study, we examined the association between non-aspirin NSAID use and functional outcomes from stroke.

2. Methods

The Women's Health Study (WHS) was a large, randomized clinical trial designed to test the effects of low-dose aspirin and vitamin E in the

* Corresponding author at: 900 Commonwealth Avenue, Brigham and Women's Hospital Division of Preventive Medicine, Boston, MA 02215United States. Tel.: +1 617 278 0878; fax: +1 617 731 3843.
E-mail address: prist@mail.harvard.edu (P.M. Rist).

primary prevention of cardiovascular disease and cancer, respectively. The design, methods, and main results have been described previously [5–7]. At the start of the WHS (1993–1996), 39,876 US female health professional aged ≥45 years without a history of cardiovascular disease, cancer, or other major illnesses were randomized to receive active aspirin and placebo vitamin E, active vitamin E and placebo aspirin, both active agents or both placebos. After the end of the clinical trial in March 2004, follow-up of the women continued on an observational basis. Twice within the first year of the trial and yearly thereafter, the women were sent questionnaires asking about demographic information, lifestyle characteristics, medical history, and the occurrence of study endpoints (including stroke and transient ischemic attacks (TIAs)).

The WHS was approved by the institutional review board at Brigham and Women's Hospital. All participants provided written informed consent.

2.1. Exposure assessment

To be enrolled in the WHS, the women either had to be not currently taking NSAIDs or indicate that they were willing to forego their usage of NSAIDs during the trial. This requirement helped to ensure that at baseline study participants did not have strong indications or contraindications for NSAID use and substantially reduces confounding by indication to use NSAIDs at study entry.

On each yearly follow-up questionnaire (except for the 6th year of observational follow-up), the women were asked "During the past month, on approximately how many days did you take any of the following (do not count your study pills): Nonsteroidal, anti-inflammatory agents (e.g., Motrin, Advil, Nuprin, Naprosyn, Feldene, Mediprin)." Possible response options were: 0, 1–3, 4–10, 11–20 or ≥21 days in the past month. The women's responses to each of the yearly follow-up questionnaires were used to determine their NSAID use for the following year. We imputed NSAID use for the 6th year of observational follow-up using the women's responses from the 5th year of follow-up. We grouped the women into three different categories of NSAID use at each study time point: non-user (0, 1–3, or 4–10 days of use in the past month); user (11–20 or ≥21 days of use in the past month); and missing (did not answer the question about NSAID use) from study entry until the date of first stroke or TIA event, death, last documented contact, or end of the study, whichever occurred first.

2.2. Outcome assessment

If a woman reported the occurrence of a TIA or stroke in her yearly questionnaire, we asked for permission to review her medical records. An Endpoints Committee of physicians (including a board-certified vascular neurologist) reviewed the medical records and decided whether or not to confirm cases of TIA or stroke. A TIA was defined as a focal neurologic deficit of sudden or rapid onset and vascular mechanism that resolved within 24 h. A nonfatal stroke was defined as a focal neurologic deficit of sudden or rapid onset and vascular mechanism that lasted >24 h. To confirm cases of fatal stroke, all available sources, including death certificates and hospital records, were reviewed to determine if there was evidence of a cerebrovascular mechanism. The Endpoints Committee classified the strokes according to major subtype (ischemic, hemorrhagic, or unknown) with excellent interobserver agreement (Cohen's $\kappa = 0.96$) [8]. For this analysis, we used only confirmed cases of ischemic stroke. Women who experienced a hemorrhagic stroke or stroke of unknown type were censored at the time of stroke onset. Additionally, the Endpoints Committee assigned each confirmed stroke a modified Rankin Scale (mRS) score based on the degree of impairment experienced by the patient at hospital discharge. The seven-point mRS score (0 = no symptoms at all; 1 = no significant disability despite symptoms; 2 = slight disability; 3 =

moderate disability; 4 = moderately severe disability; 5 = severe disability; 6 = death) [9,10] was a priori categorized into three levels (0 to 1, 2 to 3, and 4 to 6) for our analyses to avoid possible problems with model convergence due to sparse data, an approach consistent with a previous study in the WHS [11]. Therefore our possible outcome categories were: no stroke or TIA, TIA, or ischemic stroke with the three possible categories of the mRS. In the event that a woman experienced multiple strokes and/or TIAs, only the first event was used for our analysis.

2.3. Confounder scores

Although the participants in the WHS were free of many major medical conditions at baseline, conditions may have developed over the course of the study. To adjust for confounding by other medical conditions that may cause a participant to use NSAIDs and may also increase their risk of a poor functional outcome from stroke, we constructed a modified version of the Charlson comorbidity index [12]. We modified the score because we did not have information on renal and liver disease severity. All liver disease was categorized as mild and all renal disease as moderate to severe similar to previous studies [13,14]. Solid tumors which were either localized or metastatic at presentation received a score of 2 and 6, respectively.

We also constructed scores for indications of NSAID use and NSAID side effects or contraindications to adjust for potential confounding by these factors [13]. To calculate the score for indications of NSAID use, we assigned one point for each of the following conditions: migraine, frequent headache (reported ≥3 times), osteoarthritis, inflammatory arthritis, and coronary artery disease. To calculate the score for NSAID side effects or contraindications, we assigned one point for each of the following: gastrointestinal bleeding, peptic ulcer, and gastrointestinal symptoms (nausea, vomiting, dyspepsia and dysphagia).

2.4. Statistical analysis

We excluded women who reported a history of TIA or stroke at baseline. We used four separate Cox proportional hazards models with time-varying exposure values to determine the relative risk of experiencing a TIA or ischemic stroke with mRS 0-1, 2-3, or 4-6 compared to not experiencing a TIA or stroke. All other outcome events that were not the outcome of interest for that Cox model were censored at the time of the event. Women contributed person-time from the receipt of the baseline questionnaire until the date of first stroke or TIA event, death, last documented contact, or end of the study, whichever occurred first. Exposure status was updated on a yearly basis based on responses to yearly questionnaires. To test the assumption of proportional hazards, we included an interaction term between the log transformation of time in the study and NSAID use and no violation was found.

We adjusted for the following potential confounders: age (continuous), smoking status (never, past, current), alcohol consumption (rarely/never, 1-3 drinks/month, 1-6 drinks/week, ≥1 drink/day), exercise (<200, 200 to 599, 600 to 1499, ≥1500 kcal/ week), history of high cholesterol (yes/no), cholesterol lowering medication use (yes/no), history of hypertension (yes/no), hypertension medication use (yes/no), body mass index (continuous), modified Charlson comorbidity score (continuous), indications of NSAID use score (continuous) and NSAID side effects or contraindications score (continuous). In addition we adjusted for randomized treatment assignment to aspirin and vitamin E. The modified Charlson comorbidity score and the scores for indications of NSAID use and NSAID side effects or contraindications were updated on a yearly basis. All other variables were assessed at baseline and not updated over time.